diabetes studies

Some of you may have seen the headlines this week about JDRF and Amylin investigating a new diabetes treatment — essentially a mixture of insulin and pramlintide (brand name Symlin), two substances that are only FDA approved for entirely separate use at the moment. Interesting!
The reasoning seems highly practical: “A co-formulated therapy that harnesses the benefit of both hormones might better mimic the natural physiology of the pancreas and simplify dosing decisions.”
Also in…